Abstract Celecoxib has proved to be an enigma as a potential anticancer agent. COX-2 inhibition is not necessarily involved in its mechanism of cytotoxicity, and it induces a non-classical apoptotic pathway leading to cell death in some cell culture models. Because the classical pathways are not always induced by celecoxib, we hypothesized that celecoxib might be working as a σ2 receptor agonist as part of its cytotoxicity. In addition, published research has supported the therapeutic potential of σ2 receptor agonists in cancer chemotherapy. We have determined that celecoxib will inhibit the CRL-1620 cell line with an IC50 of 32 μM, and the 9L rat glioma model with an IC50 of 60 μM. Using a group of 41 high affinity σ2 receptor selective agonists and following a ligand-based drug design approach, we have developed a four-site pharmacophore model for σ2 receptor agonists. Upon aligning celecoxib to this model, it matched three of the four sites, further supporting our hypothesis that celecoxib might be working as a σ2 receptor agonist as part of its cytotoxicity. Additional compounds have been developed utilizing the celecoxib scaffold as σ2 receptor agonist anticancer agents. From the pharmacophore model we also developed an in silico model for the σ2 receptor binding pocket as it has not been cloned nor has its three dimensional structure been determined. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 737.
Read full abstract